NCT07003295 2026-03-19
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
15 trialsNCT04703686 2026-03-16
Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy
The Lymphoma Academic Research Organisation
Phase 2 Completed
NCT06558604 2026-02-11
GLOASIS
The Lymphoma Academic Research Organisation
Phase 2 Recruiting
NCT02896582 2026-01-14
LyMa101
The Lymphoma Academic Research Organisation
Phase 2 Completed
NCT07261163 2025-12-03
Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting
NCT06252675 2025-10-22
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
University of California, San Francisco
Phase 2 Recruiting
NCT03863184 2025-06-06
Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT06656221 2024-11-19
A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma
Ruijin Hospital
Phase 2 Not yet recruiting
NCT03311126 2024-10-24
Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma
University of Wisconsin, Madison
Phase 2 Terminated
NCT06504199 2024-08-09
ZGR
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT06427213 2024-05-23
This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma
Henan Cancer Hospital
Phase 2 Not yet recruiting
NCT06324994 2024-03-22
Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.
Dalian Medical University
Phase 2 Not yet recruiting
NCT05833763 2024-01-08
GOlDiLOX
Australasian Leukaemia and Lymphoma Group
Phase 2 Recruiting
NCT03229382 2023-08-16
OPERA-PLRG10
Polish Lymphoma Research Group
Phase 2 Terminated
NCT02736617 2022-01-05
Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma
OHSU Knight Cancer Institute
Phase 2 Completed